Humacyte Announces Presentation of Symvess® Long-Term Safety and Efficacy Results at VESS MeetingGlobeNewsWire • 02/18/26
Humacyte, Inc. (HUMA) Falls More Steeply Than Broader Market: What Investors Need to KnowZacks Investment Research • 02/11/26
Humacyte Announces New U.S. Department of Defense Funding for Procurement of Bioengineered Blood VesselsGlobeNewsWire • 02/09/26
Humacyte, Inc. (HUMA) Exceeds Market Returns: Some Facts to ConsiderZacks Investment Research • 02/03/26
Humacyte Announces Hospital Charge Data Showing High Expense of Preventable Extremity Arterial Injury ComplicationsGlobeNewsWire • 01/08/26
Is Humacyte, Inc. (HUMA) Outperforming Other Medical Stocks This Year?Zacks Investment Research • 01/07/26
Humacyte Announces Planned Marketing Authorization Application for Symvess® in IsraelGlobeNewsWire • 01/05/26
Humacyte Announces Publication of Long-Term Safety and Efficacy Results of Symvess® in Extremity Trauma RepairGlobeNewsWire • 12/22/25
Humacyte Announces Credit Facility of Up to $77.5 Million with Avenue CapitalGlobeNewsWire • 12/16/25
Wall Street Analysts See Humacyte, Inc. (HUMA) as a Buy: Should You Invest?Zacks Investment Research • 12/05/25
Humacyte Announces Presentations at VEITHsymposium Highlighting Positive Acellular Tissue Engineered Vessel (ATEV™) Clinical ResultsGlobeNewsWire • 11/20/25
Should You Invest in Humacyte, Inc. (HUMA) Based on Bullish Wall Street Views?Zacks Investment Research • 11/14/25
Humacyte Announces Six Presentations Scheduled for the Upcoming 52nd Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITHsymposium)GlobeNewsWire • 11/13/25
Humacyte Announces Third Quarter 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 11/12/25
Humacyte Announces Presentation of Positive Two-Year Results from Phase 3 Dialysis Access Trial at the American Society of Nephrology's Kidney Week 2025GlobeNewsWire • 11/10/25
Humacyte, Inc. (HUMA) Declines More Than Market: Some Information for InvestorsZacks Investment Research • 11/07/25
Humacyte to Present Third Quarter Financial Results and Provide Business Update on November 12, 2025GlobeNewsWire • 11/06/25
Humacyte Announces Publication of New Data Comparing Symvess™ to Autologous Vein in Extremity Arterial TraumaGlobeNewsWire • 10/30/25
Humacyte, Inc. (HUMA) Advances While Market Declines: Some Information for InvestorsZacks Investment Research • 10/14/25
Humacyte Announces Pricing of $60.0 Million Oversubscribed Registered Direct OfferingGlobeNewsWire • 10/07/25
Humacyte Announces Publication of Long-Term Results for Ukrainian Patients Treated in Real-World Combat Setting with Symvess™GlobeNewsWire • 10/06/25
Humacyte, Inc. (HUMA) Outperforms Broader Market: What You Need to KnowZacks Investment Research • 10/01/25